Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Oct;38(10):2243.e1-2243.e3.
doi: 10.1016/j.ajem.2020.05.042. Epub 2020 May 22.

Neuroleptic malignant syndrome in patients with COVID-19

Mitsuhito Soh  1 , Toru Hifumi  2 , Shutaro Isokawa  1 , Masato Shimizu  1 , Norio Otani  1 , Shinichi Ishimatsu  1
Affiliations
Case Reports

Neuroleptic malignant syndrome in patients with COVID-19

Mitsuhito Soh et al. Am J Emerg Med. 2020 Oct.

Abstract

We report the first two cases of Coronavirus Disease 2019 (COVID-19) who were receiving intensive care including favipiravir, and were clinically diagnosed with neuroleptic malignant syndrome (NMS) to focus attention on NMS in COVID-19 management. Case 1: A 46-year-old-man with acute respiratory distress syndrome (ARDS) caused by COVID-19 infection was being administered favipiravir. Fentanyl, propofol, and rocuronium were also given. On day 3, midazolam administration was initiated for deep sedation. On day 5, his high body temperature increased to 41.2 °C, creatine kinase level elevated, and he developed tachycardia, tachypnea, altered consciousness, and diaphoresis. NMS was suspected, and supportive therapy was initiated. High-grade fever persisted for 4 days and subsided on day 9. Case 2: A 44-year-old-man with ARDS caused by COVID-19 infection was being treated with favipiravir. On day 5, risperidone was started for delirium. On day 7, his body temperature suddenly increased to 40.8 °C, his CK level elevated, and he developed tachycardia, tachypnea, altered consciousness, and diaphoresis. NMS diagnosis was confirmed, and both, favipiravir and risperidone were discontinued on day 8. On the same day, his CK levels decreased, and his body temperature normalized on day 9. Patients with COVID-19 infection frequently require deep sedation and develop delirium; therefore, more attention should be paid to the development of NMS in patients who are being administered such causative agents. The mechanism underlying the occurrence of NMS in COVID-19 patients treated with favipiravir remains unknown. Therefore, careful consideration of NMS development is necessary in the management of COVID-19 patients.

Keywords: COVID-19; Fever; Neuroleptic malignant syndrome.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Hospital course in case 1. CRP; c-reactive protein, BT; body temperature, CK; creatinine kinase.
Fig. 2
Fig. 2
Hospital course in case 2. CRP; c-reactive protein, BT; body temperature, CK; creatinine kinase.
See this image and copyright information in PMC

Comment in

References

    1. Richardson S., Hirsch J.S., Narasimhan M., Crawford J.M., McGinn T., Davidson K.W. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020 doi: 10.1001/jama.2020.677. Published online April 22, 2020. - DOI - PMC - PubMed
    1. Grasselli G., Zangrillo A., Zanella A., Antonelli M., Cabrini L., Castelli A. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574–1581. - PMC - PubMed
    1. Diseases hJAfI Case presentations of COVID-19. http://www.kansensho.or.jp/modules/topics/index.php?content_id=31 at.
    1. Shiraki K., Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther. 2020;209 - PMC - PubMed
    1. Alhazzani W., Moller M.H., Arabi Y.M., Loeb M., Gong M.N., Fan E. Surviving Sepsis campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19) Intensive Care Med. 2020;46(5):854–887. - PMC - PubMed

Publication types

Substances